Technical analysis of Enlivex Therapeutics Ltd. (ENLV): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis.
Price Performance
| 1 month | -46.64% |
| 3 months | -91.31% |
| Year-to-date | -92.31% |
| 1 year | -94.85% |
| 3 years | -97.06% |
| 5 years | -99.54% |
52-Week Range
| 52-week High | $27.15 |
| 52-week Low | $0.79 |
| Avg Volume (90d) | 187K |
Technical Indicators
| SMA 50 | $2.64 |
| SMA 200 | $10.79 |
| Beta | 1.68 |
| 30-day Volatility (annualised) | 85.3% |
| Price vs SMA 50 | -69.3% |
| Price vs SMA 200 | -92.5% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $15.75 | |
| 2025-11 | $14.55 | -7.6% |
| 2025-12 | $10.55 | -27.5% |
| 2026-01 | $15.15 | +43.6% |
| 2026-02 | $17.25 | +13.9% |
| 2026-03 | $13.95 | -19.1% |
| 2026-04 | $12.30 | -11.8% |
| 2026-05 | $12.15 | -1.2% |
| 2026-06 | $8.25 | -32.1% |
| 2026-07 | $2.09 | -74.7% |
| 2026-08 | $1.28 | -38.8% |
| 2026-09 | $0.81 | -36.6% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $0.81 |
| Market Cap | $14M |
| Exchange | NASDAQ |
| Country | IL |
Valuation Ratios
| P/E Ratio | 0.00 |
| Price / Book | 0.00 |
| EV / EBITDA | -1.20 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 193.24 |